Why Is There No Organized Prostate Cancer Screening Program in France?
-
Key Clinical Takeaways:
- France maintains no national organized screening program for prostate cancer, as the Haute Autorité de santé does not recommend routine population-wide testing due to conflicting international trial data regarding mortality and quality of life benefits.
- The Association française d’urologie advises individual early diagnosis for men aged 50—or 45 for those with risk factors—up to age 75, utilizing PSA blood tests and digital rectal examinations.
- In the United States, the American Cancer Society updated its guidelines on November 12, 2026, recommending biennial PSA screening for average-risk men aged 50 to 69, alongside secondary tests like MRIs to prevent unnecessary biopsies.
France currently lacks a national screening program for prostate cancer because authorities have not found sufficient proof that screening reduces mortality or improves quality of life.
The Haute Autorité de santé continues to advise against systematic PSA testing in the general population, citing conflicting conclusions from major international studies. In contrast, the Association française d’urologie recommends individual early diagnosis between the ages of 50 and 75, or starting at 45 for patients with specific risk factors.
The diagnostic framework relies primarily on a blood test to measure specific prostate antigen levels alongside a digital rectal examination. When tests yield elevated results, clinical protocols frequently require repeating the PSA draw within two weeks to three months to account for non-cancerous variables such as benign prostatic hyperplasia or inflammation.
The American Cancer Society revised its guidelines on November 12, 2026, to establish a more precise schedule using PSA blood draws and secondary imaging like magnetic resonance imaging prior to performing biopsies. Ces mises à jour des lignes directrices recommandent un dépistage annuel de 45 à 69 ans spécifiquement pour les hommes noirs, qui font face à un taux de mortalité près de deux fois supérieur à celui des patients blancs.

Des spécialistes du centre hospitalier intercommunal de Fréjus Saint-Raphaël ont organisé des conférences publiques et des dépistages gratuits à l’Estérel Arena le 12 novembre, suivis d’un événement de dépistage le 14 novembre, pour aborder une maladie qui touche un homme sur sept en France et représente 8 100 décès et plus de 50 000 nouveaux cas chaque année.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
